Introduction
============

Because highly active antiretroviral treatment (HAART) has transformed human immunodeficiency virus (HIV) infection from a progressively deteriorating fatal disease to a long-term, controllable condition, an increasing number of HIV-infected patients are living to an advanced age. As a consequence, these patients are being diagnosed with chronic diseases that contribute to renal impairment, including hypertension, atherosclerotic cardiovascular disease, and diabetes mellitus.[@b1-hiv-3-001],[@b2-hiv-3-001] Kidney function has been reported to be abnormal in up to 30% of HIV-infected patients.[@b3-hiv-3-001] African Americans comprise nearly one-half (48%) of all US HIV/autoimmune deficiency syndrome (AIDS) cases, acquire HIV infection at seven times the rate of Caucasians, and are nearly twice as likely to have diabetes mellitus.[@b4-hiv-3-001],[@b5-hiv-3-001] Thus, they appear more predisposed than Caucasians to developing HIV-associated nephropathy (90% of all reported cases) and cardiovascular disease.[@b6-hiv-3-001]--[@b9-hiv-3-001]

Hispanics account for 17% of US HIV/AIDS cases and have a 2.5-fold higher rate of acquiring new HIV infections compared with nonHispanic Caucasians.[@b10-hiv-3-001] Because Hispanics more frequently have diabetes and experience more diabetes-related end-stage renal disease than non-Hispanic Caucasians,[@b10-hiv-3-001]--[@b12-hiv-3-001] they would in theory be at greater risk of worsening renal function if given antiretroviral drugs that adversely affect the glomeruli or proximal tubules or which exacerbate diabetes by inducing insulin resistance.

Many studies have been performed to evaluate risk factors that may contribute to renal impairment or renal failure in HIV-infected patients.[@b13-hiv-3-001]--[@b27-hiv-3-001] Some have linked certain antiretroviral drugs, especially tenofovir disoproxil fumarate (TDF) and the protease inhibitors lopinavir/ritonavir, atazanavir/ritonavir, indinavir and saquinavir/ritonavir, with reduction in estimated glomerular filtration rate (eGFR) and renal tubular abnormalities.[@b28-hiv-3-001],[@b29-hiv-3-001] Few of these studies have examined populations in which the majority of patients are African American or Hispanic. Most renal risk assessments have used the Cockcroft-Gault (CG) method of calculating creatinine clearance (CrCl), from which a value for eGFR can be extrapolated.[@b30-hiv-3-001] The CG-estimated eGFR incorporates body weight and gender. It may be less accurate than the Modification of Diet in Renal Disease (MDRD) method,[@b31-hiv-3-001] which has adjustment factors for female gender and African American race. The purpose of the current study was to evaluate the relationship between demographics, antiretroviral/ nonantiretroviral medication, comorbidities, duration of HIV, duration of HAART, viral load, and CD4+ cell counts on the development of a \>25% reduction in eGFR, as estimated by both the CG and MDRD equations, in a predominantly African American and Hispanic outpatient HIV clinic population.

Methods
=======

This retrospective, single-center, Phase IV electronic database study was conducted at the AIDS Arms Peabody Health Center in Dallas, Texas, a large outpatient HIV clinic that services the health care needs of a primarily African American and Hispanic HIV population. Medical records of 691 clinic patients followed for up to four years (2003--2008) were reviewed. Data that were collected from these records and tabulated included demographics, laboratory values, viral load, CD4+ cell count, comorbidities (hypertension, diabetes mellitus, anemia, hepatitis C \[HCV\], and HBV), history of antiretroviral and nonantiretroviral drugs received (with start, stop and change dates), and medication adherence history as assessed by prescription refill records. Nucleoside reverse transcriptase inhibitors for which usage data were available included zidovudine, stavudine, didanosine, lamivudine, abacavir, TDF, emtricitabine, the lamivudine-zidovudine fixed-dose combination tablet, the abacavir-lamivudine- zidovudine f ixed-dose combination tablet, the TDF-emtricitabine fixed-dose combination tablet, and the abacavir-lamivudine fixed-dose combination tablet. Usage data were also available for the non-nucleoside reverse transcriptase inhibitors efavirenz, nevirapine, and delavirdine, and for the protease inhibitors atazanavir, nelfinavir, lopinavir/ ritonavir, fosamprenavir, saquinavir, indinavir, and ritonavir. Package inserts for antiretroviral agents were consulted before these agents were prescribed to ensure appropriate dosing regimens based on baseline laboratory tests. No special renal function requirements outside of product labeling were applied for any individual antiretroviral, including TDF. Data were analyzed only for HAART-treated patients who had been monitored continuously at the Peabody Health Center for at least one year, comparing disease treatment characteristics of patients whose eGFR fell by more than 25% from baseline with those having no eGFR change.

The eGFR was assessed two ways. First, it was estimated from CrCl values calculated by the CG formula:[@b30-hiv-3-001]
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where CrCl is expressed in mL/min, age in years, weight in kilograms, and serum creatinine in mg/dL. Second, eGFR was calculated by the MDRD formula:[@b31-hiv-3-001]
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Study endpoints included time from HAART initiation to event (eGFR decreasing by \>25% from baseline) in the entire study group and the TDF-treated versus non- TDF- treated subgroups, and the effect of comorbidities and concomitant antiretroviral and nonantiretroviral medications on time to \>25% decrease in eGFR from baseline. Statistical analyses were primarily descriptive, although a proportional hazards model was used to analyze time to event (calculated \>25% eGFR decrease from baseline), with subanalysis of TDF-treated versus non-TDF-treated patients. Variation in treatment duration and other variables that could possibly contribute to renal impairment were factored into the model building process. Statistical analysis was performed by MDC-Biomed Data Sciences-ID at GlaxoSmithKline.

Results
=======

Data from a total of 323 patients who had been treated with HAART for at least one year were evaluated ([Table 1](#t1-hiv-3-001){ref-type="table"}). Most (82%) were males, and the racial/ethnic distribution was 61% African American, 19% Caucasian, 12% Hispanic, and 8% other. Mean age was 37.9 years, and mean weight was 75.4 kg. Of the comorbidities examined, about one-third of the patients were HCV-positive (34%), 29% were hypertensive, 6% were HBV-positive, and 3% were diabetic. Fifty-two percent had been TDF-treated and 48% non- TDF-treated. Mean baseline MDRD-assessed eGFR was 114.5 mL/min/1.73 m^2^; and mean CG-assessed eGFR was 120.6 mL/min/1.73 m^2^. The mean (± standard deviation \[SD\]) time on study for HAART-exposed patients monitored for at least one year was the same in the TDF-treated and non- TDF-treated groups (2.7 years \[SD, 1.0 year\]). The mean time patients were specifically exposed to TDF-based HAART was 1.8 years (SD, 1.3 years), and the time patients were exposed to non-TDF-based HAART was 1.7 years (SD, 1.3 years).

Using CG-assessed eGFR, proportional hazards analysis showed age, weight, and time on study significantly predicted a \>25% decline from baseline in eGFR ([Table 2](#t2-hiv-3-001){ref-type="table"}). For each year of increase in age at baseline, the hazard of having a \>25% decline from baseline in CG eGFR increased by 3.9%. For each unit increase in weight, the hazard of having a \>25% decline from baseline in CG eGFR decreased by 1%, and for each additional day in the study, it decreased by 0.1%. Using MDRD-calculated eGFR, proportional hazards analysis showed that time on study and a diagnosis of hypertension at baseline significantly predicted a \>25% eGFR decline ([Table 2](#t2-hiv-3-001){ref-type="table"}). For each additional day in the study, the hazard of having a \>25% decline from baseline in MDRD-assessed eGFR decreased by 0.1%. Patients with a diagnosis of hypertension at baseline were 1.7 times more likely to have a \>25% decline from baseline in MDRD eGFR than those who were not hypertensive at baseline.

Factors that did not show a significant predictive value of a \>25% decline by either method of assessing eGFR were type of antiretroviral/nonantiretroviral medications coadministered, certain comorbidities (HCV and HBV infection), and the magnitude of CD4+ counts and viral load. Because only 3% of the patients were diabetics, too few were involved to allow a risk factor analysis of a diagnosis of diabetes mellitus on renal function.

Discussion
==========

Studies of renal impairment risks in antiretroviral-treated HIV patients have reported discordant results, possibly due to differences between studies in the definition of renal impairment applied, racial proportions evaluated, laboratory values monitored, size of populations examined, duration over which patients were assessed or had received HAART, types of HAART agents used, and inclusion of patients with baseline low eGFR in some studies but not others.[@b13-hiv-3-001]--[@b27-hiv-3-001] Renal risk factors in a predominantly African American/Hispanic HIV population have undergone limited study to date, despite these populations having a faster rate of acquiring HIV infection relative to other racial or ethnic groups.[@b6-hiv-3-001],[@b10-hiv-3-001],[@b32-hiv-3-001],[@b33-hiv-3-001]

Our retrospective database study in a primarily (73%) African American or Hispanic HIV cohort showed that time on study, hypertension, weight, and age were the only significant predictors of an eGFR decrease \>25% from baseline, and that TDF or any other specific antiretroviral agent or combination used, other comorbidities, baseline viral load, and baseline CD4+ count did not affect this endpoint. Our finding that increased time on study (and, hence, on HAART) was associated with a decline in renal function is at odds with what has been reported in several case reports and studies in which eGFR either improved or HIV-associated nephropathy progression slowed after HAART initiation.[@b34-hiv-3-001]--[@b38-hiv-3-001] A reason for this discrepancy may stem from our population having had a higher mean baseline eGFR (120.6 mL/min/1.73 m^2^ by CG estimation and 114.5 mL/min/1.73 m^2^ by MDRD) compared with the HIV populations in whom improved renal function has been reported after HAART initiation. This reason is corroborated by data from the large Centers for AIDS Research Network of Integrated Clinical Systems (n = 4770), which showed that one year after HAART was started in previously treatment-naïve patients, MDRD-assessed eGFR improved in patients with chronic kidney disease at baseline (eGFR \< 60 mL/min/1.73 m^2^), but decreased in patients with initially normal renal function.[@b39-hiv-3-001] Another factor that might explain the decrease rather than increase in renal function in our patient population is the fact that our study included a large proportion of African Americans, and the latter have a much faster rate of progression to end-stage renal disease than do Caucasian populations, thus making the decrements in eGFR in our African American cohort likely to outweigh increments in other study patients.[@b40-hiv-3-001]

In a larger study involving primarily African American patients from the Philadelphia area (n = 500; 67% African American), Short et al[@b21-hiv-3-001] similarly found over one year that TDF therapy did not cause a significant change in MDRD-estimated eGFR compared with a non-TDF-treated control arm, and that gender and diabetes were not risk factors for renal impairment. However, unlike our study, these investigators saw a significant increase in eGFR in patients receiving non-TDF-containing regimens, and found that hypertension, weight, or age did not confer greater renal impairment risk.

In one other renal risk study in a predominantly African American population (89% African American, 28% treatmentnaïve, mean HAART exposure 16 months),[@b17-hiv-3-001] multivariate regression analysis showed diabetes, hyperlipidemia, baseline MDRD-calculated eGFR \> 90 mL/min/1.73 m^2^, and TDF use were associated with greater decreases in eGFR. TDF effects remained significant at six months (*P* \< 0.05) and at the end of therapy (*P* = 0.05) after adjustment for age and baseline eGFR. A subgroup comparison of TDF-treated patients (n = 150) and abacavir-treated patients (n = 68) showed that 17% of the TDF group and 9% of the abacavir group experienced an eGFR decrease \>30 mL/min/1.73 m^2^, and that change in eGFR at one year was greater with TDF (−11.48 versus −3.91 mL/min/1.73 m^2^ for abacavir). Our study included 110 patients who had taken abacavir as part of HAART regimens for at least one year, and baseline mean eGFR did not differ between patients on abacavir ( CG-estimated: 121 mL/min/1.73 m^2^; MDRD: 113.7 mL/min/1.73 m^2^) and the 167 patients on TDF ( CG-estimated: 120.0 mL/min/1.73 m^2^; MDRD-estimated: 114 mL/min/1.73 m^2^), with over 80% of patients in each group having a baseline eGFR ≥ 60 mL/min/1.73 m^2^ by either calculation method (data not shown). As we found with TDF, use of abacavir was not associated with our particular endpoint, ie, an increased risk of \>25% decrease in eGFR. However, it is of note that our study was not powered to compare TDF regimens with abacavir regimens regarding renal function change.

The renal impairment risk factors we observed in a predominantly African American/Hispanic cohort are comparable with those reported in US or European studies in large HIV-infected Caucasian populations and in studies in black patients in Africa.[@b13-hiv-3-001]--[@b16-hiv-3-001],[@b18-hiv-3-001]--[@b20-hiv-3-001],[@b22-hiv-3-001]--[@b27-hiv-3-001],[@b29-hiv-3-001],[@b41-hiv-3-001] However, in all but two of these studies,[@b24-hiv-3-001],[@b41-hiv-3-001] TDF use was associated with either increased renal risk or greater reduction in eGFR compared with non-TDF users. It is possible that differences between our study results and those of other studies could have resulted from the definition of renal impairment we applied. The largest cohort analysis was a Center for Disease Control-sponsored evaluation of medical records of 9535 HIV-infected persons receiving HAART in 10 US cities during 2000--2003, from whom 34,814 six-month person-observations were made (3489 \[10%\] from TDF users and 31,325 \[90%\] from non-TDF users).[@b15-hiv-3-001] Multivariate analysis after 1.5 years (median) of follow-up showed that TDF use increased renal impairment risk (defined in the study as an eGFR decrease to \<90 mL/min) by 1.6 fold, as did hypertension by 1.5-fold, congestive heart failure by 1.9-fold, hemoglobin (\<8 mg/dL) by 4.7-fold, and CD4+ cell count (\<50 cells/mm^3^) by 1.5-fold. Gender, viral load (\>100,000 copies/ mL), diabetes, wasting syndrome, and weight loss (\>10 pounds or 10%) did not notably affect renal risk.[@b15-hiv-3-001] In the large French ANRS CO3 Aquitaine Cohort in 2588 HIV-infected patients in whom the median baseline CG-calculated eGFR was 96 mL/min/1.73 m^2^, multivariate analysis showed that the occurrence of eGFR \< 80 mL/min/1.73 m^2^ was increased significantly by age \>50 years compared with younger age groups (odds ratio \[OR\] = 13.3, *P* \< 0.0001), age 41--50 years compared with younger age groups (OR = 2.5, *P* \< 0.0001), baseline body mass index \<22 (OR = 3.8, *P* \< 0.0001), female gender (OR = 3.2, *P* \< 0.0001), and TDF use for at least one year (OR = 1.6, *P* = 0.0016).[@b16-hiv-3-001] The Swiss HIV Cohort study compared time to a 10-mL/min/1.73 m^2^ reduction in CG-estimated eGFR over 24 months in treatment-naïve patients or patients with treatment interruptions ≥ 12 months after starting either a TDF-based combination antiretroviral therapy (n = 363) or a TDF-sparing regimen (n = 715).[@b13-hiv-3-001] In the multiple Cox model, the risk of reaching the primary endpoint was increased most notably by concurrent diagnosis of diabetes mellitus (hazard ratio \[HR\] = 2.3, *P* = 0.008), TDF use (HR = 1.8, *P* = 0.0001) and boosted protease inhibitor use (HR = 1.7, *P* = 0.0001).

EuroSIDA, a large cohort study in 6843 HIV-positive people in Europe, determined factors that affect the onset of chronic kidney disease.[@b29-hiv-3-001] Chronic kidney disease was defined as either confirmed (at least three months apart) eGFR of 60 mL/min/1.73 m^2^ or less for patients with baseline eGFR of above 60 mL/min per 1.73 m^2^ or a confirmed 25% decline in eGFR for patients with baseline eGFR of 60 mL/min/1.73 m^2^ or less. Poisson regression was used to determine factors associated with chronic kidney disease. Two hundred and twenty-five (3.3%) people progressed to chronic kidney disease during 21,482 person-years follow-up, ie, an incidence of 1.05 per 100 person-years follow-up (95% confidence interval \[CI\] 0.91--1.18); median follow-up was 3.7 years (interquartile range 2.8--5.7). Diagnosis of an AIDS-defining event, female gender, older age, developing diabetes, being hypertensive, and being HCV antibody-positive were all associated with an increased risk of chronic kidney disease. After adjustment for traditional factors associated with chronic kidney disease and other confounding variables, increasing cumulative exposure to TDF (incidence rate ratio \[IRR\] per year 1.16, 95% CI 1.06--1.25, *P* \< 0.0001), indinavir (IRR 1.12, 95% CI 1.06--1.18, *P* \< 0.0001), atazanavir (IRR 1.21, 95% CI 1.09--1.34, *P* = 0.0003) and lopinavir/ritonavir (IRR 1.08, 95% CI 1.01--1.16, *P* = 0.030) was associated with a significantly increased rate of chronic kidney disease.

Our study examined both CG- and MDRD-estimated eGFR changes because adjustments for body surface area and African American race differ respectively between the CG and MDRD methods. Higher average serum creatinine level (due to increased muscle mass) is one hypothesis for the racial difference.[@b42-hiv-3-001] Our CG-based mean eGFR values consistently exceeded MDRD-based values by about 5--10 mL/min/1.73 m^2^. This magnitude of discordance between the two methods of estimating eGFR has been reported previously,[@b43-hiv-3-001] and occasionally when both CG- and MDRD-based estimations have been used to evaluate renal function in the same population, one method has suggested an increase from baseline in eGFR and the other suggested a decrease.[@b39-hiv-3-001] With each method of assessing eGFR, time on study was observed as a significant risk for renal impairment. However, age and weight only were significant risks according to the CG-estimated eGFR calculation method, as was hypertension only by the MDRD method. This underscores the fact that using different methods of calculating eGFR can lead to different risk assessment results. Indeed, the Swiss HIV Cohort Study found general consistency between CG- and MDRD-calculated risk factors for renal impairment (defined as time to a 10 mL/min/1.73 m^2^ reduction in eGFR), but, as in our study, notable discrepancies in risk factors were observable between the CG and MDRD calculation methods. The Swiss HIV Cohort found female gender and diabetes to be significant risk factors only by CG and presence of elevated systolic blood pressure and presence of AIDS only by MDRD.[@b13-hiv-3-001]

Because we did not assess renal tubular dysfunction or proteinuria in our study, this limited our ability to obtain a more complete picture of the renal condition of the study patients. Findings of other studies that did look at tubular status, by examining additional parameters such as spot-urine protein creatinine ratio and 24-hour markers of kidney tubulopathy (glycosuria, hyperaminoaciduria, hyperphosphaturia, and urinary β~2~-microglobulinuria), suggest that eGFR alone may not predict other pathology occurring in the kidney.[@b41-hiv-3-001],[@b44-hiv-3-001]--[@b46-hiv-3-001] Thus, in the Swiss HIV Cohort study (n = 1202), although TDF use was associated with only a mild to moderate decrease in eGFR, logistic multivariable regression analysis showed that TDF treatment in the absence of a concurrent protease inhibitor was associated with a 3.3-fold higher risk of proximal renal tubulopathy (*P* = 0.001).[@b47-hiv-3-001] Another limitation of our study was that the sample was not large enough to discern statistical differences between African American, Hispanic, and Caucasian subpopulations.

In conclusion, our retrospective database study in a predominantly African American/Hispanic cohort showed time on study, hypertension, weight, and age to be the only significant predictors of an eGFR decrease \>25% from baseline.
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###### 

Baseline characteristics by tenofovir (TDF) status for antiretroviral therapy-exposed patients at least one year on study

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                           TDF+\                                                  TDF −\                                                  Total\
                                           n = 167                                                n = 156                                                 n = 323
  ---------------------------------------- ------------------------------------------------------ ------------------------------------------------------- ----------------------------------------------------------
  Gender, n (%)                                                                                                                                           

   Female                                  38 (23%)                                               21 (13%)                                                59 (18%)

   Male                                    129 (77%)                                              135 (87%)                                               264 (82%)

  Age, years                                                                                                                                              

   Mean (SD)                               37.4 (8.0)                                             38.4 (9.0)                                              37.9 (8.5)

  Race, n (%)^b^                                                                                                                                          

   Black                                   96 (57%)                                               102 (65%)                                               198 (61%)

   White                                   41 (25%)                                               21 (13%)                                                62 (19%)

   Hispanic                                19 (11%)                                               21 (13%)                                                40 (12%)

   Other                                   11 (7%)                                                12 (8%)                                                 23 (7%)

  HIV-1 RNA (log~10~ copies/mL)                                                                                                                           

   Median (range)                          3.96 (1.69--5.75)                                      3.74 (1.69--5.87)                                       3.86 (1.69--5.87)

  CD4 cell count (cells/mm^3^)                                                                                                                            

   Median (range)                          298 (8--1664)                                          430 (4--1694)                                           343 (4--1694)

  Weight (kg)                                                                                                                                             

   Mean (SD)                               75.1 (15.3)                                            75.6 (15.6)                                             75.4 (15.4)

  Hepatitis B status                                                                                                                                      

   Positive                                13 (8%)                                                6 (4%)                                                  19 (6%)

  Hepatitis C status                                                                                                                                      

   Positive                                57 (34%)                                               54 (35%)                                                111 (34%)

  Hypertension                                                                                                                                            

   Yes                                     50 (30%)                                               44 (28%)                                                94 (29%)

  Diabetes                                                                                                                                                

   Yes                                     1 (\<1%)                                               10 (6%)                                                 11 (3%)

  Cockcroft-Gault CrCl category (mL/min)                                                                                                                  

   \<30                                    0                                                      1 (\<1%)                                                1 (\<1%)

   30--60                                  2 (1%)                                                 3 (2%)                                                  5 (2%)

   ≥60                                     140 (84%)                                              131 (84%)                                               271 (84%)

   Missing                                 25 (15%)                                               21 (13%)                                                46 (14%)

   Mean (SD)                               120 (45.6)[\*](#tfn2-hiv-3-001){ref-type="table-fn"}   121.2 (36.2)[‡](#tfn4-hiv-3-001){ref-type="table-fn"}   120.6 (41.2)[\|\|](#tfn6-hiv-3-001){ref-type="table-fn"}

  MDRD GFR category (mL/min)                                                                                                                              

   \<30                                    0                                                      1 (\<1%)                                                1 (\<1%)

   30--60                                  1 (\<1%)                                               1 (\<1%)                                                2 (\<1%)

   ≥60                                     143 (86%)                                              134 (86%)                                               277 (86%)

   Missing                                 23 (14%)                                               20 (13%)                                                43 (13%)

   Mean (SD)                               114 (44.4)[†](#tfn3-hiv-3-001){ref-type="table-fn"}    115 (26.4)[§](#tfn5-hiv-3-001){ref-type="table-fn"}     114.5 (36.7)[¶](#tfn7-hiv-3-001){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** n values for certain parameters measured were as follows:

n = 142;

n = 144;

n = 135;

n = 136;

n = 277;

= 280.

**Abbreviations:** CrCl, creatinine clearance; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; SD, standard deviation.

###### 

Summary of proportional hazards model for Cockcroft-Gault CrCl and MDRD-calculated GFR using stepwise selection method in antiretroviral therapy-exposed patients at least one year on study

  Variable (n = 162)     Parameter estimate (SD)   *P* value   Hazard ratio
  ---------------------- ------------------------- ----------- --------------
  **CG method**                                                
  CG-estimated CrCl      0.0136 (0.0019)           \< 0.0001   1.014
  Age, years             0.0381 (0.0143)           0.0077      1.039
  Weight (lbs)           −0.0128 (0.0042)          0.0023      0.987
  Time on study (days)   −0.0013 (0.0004)          0.0043      0.999
  **MDRD method**                                              
  MDRD-estimated GFR     0.0120 (0.0016)           \< 0.0001   1.012
  Time on study (days)   −0.0012 (0.0004)          0.0017      0.999
  Hypertension           0.5342 (0.2213)           0.0158      1.706

**Abbreviations:** CrCl, creatinine clearance; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease; SD, standard deviation; CG, Cockcroft-Gault.
